Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.

Autor:	Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany., Vender R; Dermatrials Research Inc., Hamilton, ON, Canada., de Rie MA; Department of Dermatology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Conrad C; Department of Dermatology, Lausanne University Hospital, Switzerland., Pariser DM; Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA.; Virginia Clinical Research, Inc., Norfolk, VA, USA., Strober B; Yale University, New Haven, CT, USA.; Central Connecticut Dermatology Research, Cromwell, CT, USA., Vanvoorden V; UCB Pharma, Brussels, Belgium., Wang M; UCB Pharma, Raleigh, NC, USA., Madden C; UCB Pharma, Raleigh, NC, USA., de Cuyper D; UCB Pharma, Brussels, Belgium., Kimball AB; Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	The British journal of dermatology [Br J Dermatol] 2023 Jan 23; Vol. 188 (1), pp. 22-31.
DOI:	10.1093/bjd/ljac021
Abstrakt:	Background: BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings. Objectives: To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalimumab from BE SURE and the BE BRIGHT open-label extension (OLE) in patients with moderate-to-severe plaque psoriasis. Methods: The 56-week double-blinded BE SURE phase III randomized controlled trial randomized patients 1 : 1 : 1 to bimekizumab 320 mg every 4 weeks (Q4W), bimekizumab 320 mg Q4W to week 16 then every 8 weeks (Q8W), or adalimumab 40 mg every 2 weeks to week 24 then bimekizumab 320 mg Q4W. After completing BE SURE, patients could enter the ongoing BE BRIGHT OLE, with possible dosing adjustments based on Psoriasis Area and Severity Index (PASI). The primary outcome in BE BRIGHT was incidence of treatment-emergent adverse events (TEAEs); safety data are reported by study period through week 104. Efficacy data are reported for the intention-to-treat population through week 104 by initial randomization group, with ≥ 90% improvement from baseline PASI (PASI 90) and 100% improvement (PASI 100) as key outcomes. Results: Of the patients randomized to bimekizumab, 158 were assigned to Q4W, and 161 to Q4W/Q8W. At week 104, PASI 90 was achieved by 91.2% and 89.7%, and PASI 100 was achieved by 72.3% and 68.1%, for Q4W and Q4W/Q8W, respectively; comparable to week 16 results. Among the 159 patients randomized to adalimumab, responses rapidly and substantially increased after the week 24 bimekizumab switch; at week 104, 96.9% and 70.2% of patients achieved PASI 90 and PASI 100 respectively. Through weeks 24-104, the three most common TEAEs in any bimekizumab-treated group were nasopharyngitis, oral candidiasis and upper respiratory tract infection. Rates of serious TEAEs were low. Conclusions: Clinical responses observed through week 16 of BE SURE in patients randomized to bimekizumab were sustained through 104 weeks of treatment, regardless of Q4W or Q8W maintenance dosing. Response rates were also sustained through week 104 in patients who switched from adalimumab to bimekizumab at week 24, and were similar to those observed in the bimekizumab groups. Bimekizumab was well tolerated with no new safety signals. Competing Interests: Conflicts of interest: See Appendix. (© The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu